Genprex, Inc. (GNPX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.5000 |
| Open | 1.5000 |
| Bid | 1.8000 x 900 |
| Ask | 1.7700 x 900 |
| Day's Range | 1.5000 - 1.7900 |
| 52 Week Range | 1.1700 - 3.6200 |
| Volume | |
| Avg. Volume | 104,193 |
| Market Cap | 84.78M |
| Beta (5Y Monthly) | -0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3950 |
| Earnings Date | May 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GNPX
Related Research
- Genprex, Inc.Daily – Vickers Top Buyers & Sellers for 04/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- PR Newswire
Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston.
- PR Newswire
Genprex to Present at Upcoming June Investor Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in June 2022.
- PR Newswire
Genprex to Present at Upcoming Investor Conference in May 2022
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes to investors at the following conference in May 2022.
